Monkeypox (mpox) in immunosuppressed patients [version 2; peer review: 1 approved, 2 approved with reservations]
The World Health Organization (WHO) proclaimed a public health emergency in July 2022 due to the emergence of Mpox (formerly monkeypox) while the globe was still dealing with the COVID-19 epidemic. The characteristics of mpox in immunocompetent individuals are well-characterized, despite difficultie...
Main Authors: | Sirwan Khalid Ahmed, Mona Gamal Mohamed, Kuldeep Dhama, Hitesh Chopra, Deepak Chandran, Nahed A. El-Shall, Eman Abdelaziz Dabou, Israa Abuijlan |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2023-04-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/12-127/v2 |
Similar Items
-
Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules
by: M.Valan Arasu, et al.
Published: (2023-05-01) -
Monkeypox and its broad clinical spectrum in immunocompromised patients: Two case reports
by: Carlos Adrián Pérez Martínez, et al.
Published: (2023-01-01) -
A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome
by: Clément Viguier, et al.
Published: (2022-12-01) -
Efficacy and Safety of Two-Drug Regimens That Are Approved from 2018 to 2022 for the Treatment of Human Immunodeficiency Virus (HIV) Disease and Its Opportunistic Infections
by: Palanisamy Sivanandy, et al.
Published: (2023-05-01) -
A case report of Mpox (Monkeypox) in male traveler
by: Salma AlBahrani, et al.
Published: (2023-06-01)